Close
4

Seqens Seqens

X

Company profile for Regenacy Pharmaceuticals

  • Webinars & Exhibitions

PharmaCompass
About the Company
Related CompaniesRelated Companies
We are developing ricolinostat to treat diabetic, chemotherapy-induced and inherited peripheral neuropathies. Ricolinostat, an oral, selective histone deacetylase 6 (HDAC6) inhibitor, has previously been clinically evaluated in over 250 patients with hematologic cancer and has demonstrated an excellent safety profile. Inhibition of HDAC6 is a novel approach to restoring normal nerve function for the potential treatment of p...
We are developing ricolinostat to treat diabetic, chemotherapy-induced and inherited peripheral neuropathies. Ricolinostat, an oral, selective histone deacetylase 6 (HDAC6) inhibitor, has previously been clinically evaluated in over 250 patients with hematologic cancer and has demonstrated an excellent safety profile. Inhibition of HDAC6 is a novel approach to restoring normal nerve function for the potential treatment of peripheral neuropathies by reestablishing the transport function of microtubules. Neurons conducting signals to and from the spinal cord into the feet and hands, are the longest cells in the body.

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Send me more info on How To Grow My Bussiness Digitally?
Regenacy Pharmaceuticals
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
303 Wyman Street, Suite 300 Waltham, MA 02451
Telephone
Telephone
(617) 415-5030
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY